Title: Referências
Course: HPV ARES > Section: Unidade 2 - Vacinação contra HPV

Descrição

Referências

AMERICAN ACADEMY OF PEDIATRICS (AAP). Red Book: 2012 report of the Committee on Infectious Diseases. 29. ed. Elk Grove Village, Illinois: American Academy of Pediatrics, 2012. p.524-530.

ANVISA (AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA). Soros e vacinas terão nomenclaturas padronizadas. 2008. Disponível em:Disponível em:<http://www.anvisa.gov.br/divulga/noticias/2008/260808_1.htm>. Acesso em: 10 jan. 2014.

BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Manual de vigilância epidemiológica de eventos adversos pós-vacinação. 2. ed. Brasília: Ministério da Saúde, 2008. 184 p.Disponível em:<http://bvsms.saude.gov.br/bvs/publicacoes/manual_pos-vacinacao.pdf>. Acesso em: 30 jan. 2014.

BRASIL. Ministério da Saúde. Instituto Nacional de Câncer. Coordenação Geral de Ações Estratégicas. Divisão de Apoio à Rede de Atenção Oncológica. Diretrizes brasileiras para o rastreamento do câncer do colo do útero. 1. ed. Rio de Janeiro: INCA, 2011. 104 p. Disponível em:<http://www1.inca.gov.br/inca/Arquivos/Diretrizes_rastreamento_cancer_colo_utero.pdf>. Acesso em: 30 jan. 2014.

BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de vigilância das doenças transmissíveis. Coordenação geral do Programa de Nacional de Imunizações. Informe técnico sobre a vacina papilomavírus humano (HPV) na atenção básica. Brasília: Ministério da Saúde, 2014.

CDC (CENTERS FOR DISEASE CONTROL AND PREVENTION). Quadrivalent human papillomavirus vaccine: Recommendations of the advisory committee on immunization practices (ACIP). MMWR, v. 56, n.  RR-2, p. 1-24, mar. 2007. Disponível em:<http://www.cdc.gov/mmwr/pdf/rr/rr5602.pdf>. Acesso em: 30 jan. 2014.

CDC (CENTERS FOR DISEASE CONTROL AND PREVENTION). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR, v. 59, n. 20, p. 630-632, may 2010. Disponível em:<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm?s_cid=mm5920a5_e>. Acesso em: 30 jan. 2014.

CRAWFORD, N. W. et al. Syncope and seizures following human papillomavirus vaccination: a retrospective case series. MJA, v. 194, n. 1, p. 16-8, jan. 2011. Disponível em:<https://www.mja.com.au/system/files/issues/194_01_030111/cra10263_fm.pdf>. Acesso em: 30 jan. 2014.

DANA, A. et al. Disponível em:<http://www.expertconsultbook.com/expertconsult/b/linkTo?type=journalArticle&isbn=978-1-4557-0090-5&title=Pregnancy+outcomes+from+the+pregnancy+registry+of+a+human+papillomavirus+type+6%2F11%2F16%2F18+vaccine&author=Dana%C2%A0A.+Buchanan%C2%A0K.M.+Goss%C2%A0M.A.&date=2009&volume=114&issue=&firstPage=1170&shortTitle=Obstet%20Gynecol >Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol, v. 114, n. 6, p. 1170-1178, dec. 2009.

DOBSON, S. R. M. et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women. JAMA, v. 309, n. 17, p. 1793-1802, may 2013. Disponível em:<http://jama.jamanetwork.com/data/Journals/JAMA/926887/joc130022_1793_1802.pdf>. Acesso em: 30 jan. 2014.

GARLAND, S. M. et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med, v. 356, n. 19, p. 1928-1943, may 2007. Disponível em:<http://www.nejm.org/doi/pdf/10.1056/NEJMoa061760>. Acesso em: 30 jan. 2014.

GUAN, P. et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer, New York, v. 131, n. 10, p. 2349-2359, nov. 2012.

INCA (INSTITUTO NACIONAL DE CÂNCER). INCA e Ministério da Saúde apresentam estimativas de câncer para 2014. 2013a. Disponível em:<http://www2.inca.gov.br/wps/wcm/connect/agencianoticias/site/home/noticias/2013/inca_ministerio_saude_apresentam_estimativas_cancer_2014. Acesso em: 30 jan. 2014.

INCA (INSTITUTO NACIONAL DE CÂNCER). Vigilância do Câncer e fatores de risco. Atlas de Mortalidade por câncer. 2013b. Disponível em:<http://mortalidade.inca.gov.br/Mortalidade/>. Acesso em: 30 jan. 2014.

KIRNBAUER, R et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Nati. Acad. Sci. USA, v. 89, n. 24, p. 12180-12184, dec. 1992. Disponível em:<http://www.pnas.org/content/89/24/12180.full.pdf+html>. Acesso em: 10 jan. 2014.

KREIMER, A. R. et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV 16/18 vaccine. JNCI, v. 103, n. 19, p.1444-1451, oct. 2011. http://jnci.oxfordjournals.org/content/early/2011/09/08/jnci.djr319.full.pdf. Acesso em: 30 jan. 2014.

MALAGÓN, T. et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis, v. 12, n. 10, p. 781-789, oct. 2012.

PAHO (PAN AMERICAN HEALTH ORGANIZATION) Vaccination: a shared responsibility. In: Meeting the Technical Advisory Group (TAG), 21., 2013, Quito, Ecuador. Final report… Quito, Ecuador:  Pan American Health Organization (PAHO), 2013. Disponível em:<http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&gid=22423%20&Itemid=270>. Acesso em: 22 out. 2013.

NEUZIL, K. M. et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA, v. 305, n. 14, p. 1424-31, apr. 2011. Disponível em:<http://jama.jamanetwork.com/data/Journals/JAMA/20324/joc15027_1424_1431.pdf>. Acesso em: 30 jan. 2014.

READ, T. R. et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect, v. 87, n. 7, p. 544-547, dec. 2011.

ROMANOWSKI, B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin, v. 7, n. 2, p. 161-169, feb. 2011.

ROWHANI-RAHBAR, A. et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine, v. 27, n. 41, p. 5612-5619, sep. 2009. Disponível em:<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749988/pdf/nihms133715.pdf>. Acesso em: 30 jan. 2014.

SCHILLER, J. T.; LOWY, D. R.; MARKOWITZ, L. E. Human papillomavirus vaccines. In: PLOTKIN, S. A.; ORENSTEIN, W. A.; OFFIT, P. A. (Ed.). Vaccines. [Edinburgh]: Elsevier; Saunders, 2013. p. 234-256.

SLADE, B. A. et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA, v. 302, n. 7, p. 750-757, aug. 2009. Disponível em:<http://jama.jamanetwork.com/data/Journals/JAMA/4476/joc90070_750_757.pdf>. Acesso em: 30 jan. 2014.

SILVA, L. J. Vacinas contra papilomavirus humano (HPV). In: FARHAT, C. K. et al (Ed.). Imunizações: fundamentos e prática. 5. ed. São Paulo: Atheneu, 2008. p .487-496.

THE FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med, v. 356, n. 19, p. 1915-1927, may 2007. Disponível em:<http://www.hu.ufsc.br/projeto_hpv/NEJM%2007%20EFIC%20HSIL.pdf>. Acesso em: 30 jan. 2014.

VILLA, L. L. et al. High sustained efficacy of a prophylatic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, v. 95, n. 11, p. 1459-1466, dec. 2006. Disponível em:<http://www.nature.com/bjc/journal/v95/n11/pdf/6603469a.pdf>. Acesso em: 30 jan. 2014.

VILLA, L. L. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, v. 6, n. 5, p. 271-278, may 2005.

WORLD HEALTH ORGANIZATION (WHO). Countries using HPV vaccine in national immunization schedule and planned introductions, May 2013. Disponível em:<http://www.who.int/nuvi/hpv/decision_implementation/en/index.html>. Acesso em: 22 out.2013.